Last reviewed · How we verify
Initial conversion and titration
This drug works by inhibiting the reuptake of serotonin and norepinephrine.
This drug works by inhibiting the reuptake of serotonin and norepinephrine. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | Initial conversion and titration |
|---|---|
| Also known as | clobazam (Onfi) |
| Sponsor | St. Joseph's Hospital and Medical Center, Phoenix |
| Drug class | SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By blocking the reuptake of these neurotransmitters, the drug increases their availability in the synaptic cleft, enhancing their effects on mood and cognition. This leads to improved mood and reduced symptoms of depression and anxiety.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Insomnia
Key clinical trials
- Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma (PHASE1, PHASE2)
- A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants (PHASE2)
- The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program (NA)
- Comparison Between Two Types of Sedation for Elective Upper Endoscopy Procedures (NA)
- The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (PHASE4)
- Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: